Encompass Health (EHC)
(Delayed Data from NYSE)
$93.05 USD
+1.43 (1.56%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $93.03 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Price, Consensus and EPS Surprise
EHC 93.05 +1.43(1.56%)
Will EHC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for EHC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EHC
Humana (HUM), Evergreen Nephrology Partner to Improve Health Outcomes
All You Need to Know About Encompass Health (EHC) Rating Upgrade to Buy
EHC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Other News for EHC
BrightSpring Health Services: Evaluating The Investment Case Seven Months Post-IPO
Here's How Much You Would Have Made Owning Encompass Health Stock In The Last 15 Years
Small-cap and mid-cap Health Care has room to rally - Roth MKM
Encompass Health price target raised by $4 at Truist, here's why
Invesco Small Cap Growth Fund Q2 2024 Review